Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT06923761	TitleEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1)	Phase Phase 1, Phase 2	Date Added 2025-04-11	Location Australia France Spain United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs	Tags MSI-H/ MMRd
NCT ID NCT06508307	TitleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors	Phase Phase 1	Date Added 2024-07-18	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06515314	TitleHRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors	Phase Phase 1	Date Added 2024-07-23	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06514651	TitleMAQ-001 in Patients With Advanced Solid Tumors	Phase Phase 1	Date Added 2024-07-23	Location France	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs	Tags MSI-H/ MMRd
NCT ID NCT06558773	TitleGSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.	Phase Phase 2	Date Added 2024-08-19	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Not yet recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT06634875	TitleIsunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS)	Phase Phase 2	Date Added 2024-10-10	Location California, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT06456515	TitleRegorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC	Phase Not Applicable	Date Added 2024-06-13	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT06149481	TitlePhase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)	Phase Phase 1, Phase 2	Date Added 2023-11-29	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs N-803, Retifanlimab, SX-682	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05990543	TitleCombination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer	Phase Phase 1, Phase 2	Date Added 2023-08-14	Location South Korea	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Nelmastobart and Capecitabine	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06008119	TitleEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	Phase Phase 3	Date Added 2023-08-23	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 1 to 10 of 299 entries